COMPASS Pathways (NASDAQ:CMPS) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a research report released on Friday,Benzinga reports.

A number of other analysts have also weighed in on the company. HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of COMPASS Pathways in a report on Tuesday, March 4th. Stifel Nicolaus assumed coverage on COMPASS Pathways in a research report on Thursday, February 27th. They set a “buy” rating and a $11.00 price objective on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 target price on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Finally, Canaccord Genuity Group decreased their price target on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $21.83.

COMPASS Pathways Price Performance

CMPS opened at $2.94 on Friday. The company has a market capitalization of $272.46 million, a price-to-earnings ratio of -1.34 and a beta of 2.29. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways has a 12-month low of $2.88 and a 12-month high of $10.31. The business’s fifty day simple moving average is $3.86 and its 200-day simple moving average is $4.73.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). On average, equities research analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On COMPASS Pathways

Hedge funds have recently added to or reduced their stakes in the business. RTW Investments LP purchased a new stake in shares of COMPASS Pathways in the fourth quarter worth about $11,714,000. Altium Capital Management LLC purchased a new stake in COMPASS Pathways in the 4th quarter worth approximately $5,384,000. Tang Capital Management LLC acquired a new stake in shares of COMPASS Pathways during the 4th quarter worth approximately $3,780,000. Nantahala Capital Management LLC increased its holdings in shares of COMPASS Pathways by 400.0% during the 4th quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock valued at $3,780,000 after purchasing an additional 800,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in shares of COMPASS Pathways in the 4th quarter valued at $2,458,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.